LU88633I2 - Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R) - Google Patents

Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R)

Info

Publication number
LU88633I2
LU88633I2 LU88633C LU88633C LU88633I2 LU 88633 I2 LU88633 I2 LU 88633I2 LU 88633 C LU88633 C LU 88633C LU 88633 C LU88633 C LU 88633C LU 88633 I2 LU88633 I2 LU 88633I2
Authority
LU
Luxembourg
Prior art keywords
trusopt
dorzolamide
pharmaceutically acceptable
acceptable salts
treatment
Prior art date
Application number
LU88633C
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88633(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/067,326 external-priority patent/US4797413A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LU88633I2 publication Critical patent/LU88633I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LU88633C 1987-06-26 1988-06-23 Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R) LU88633I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/067,326 US4797413A (en) 1986-05-14 1987-06-26 Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US07/208,314 US4863922A (en) 1984-12-12 1988-06-15 Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use

Publications (1)

Publication Number Publication Date
LU88633I2 true LU88633I2 (fr) 1995-09-01

Family

ID=26747752

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88633C LU88633I2 (fr) 1987-06-26 1988-06-23 Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R)

Country Status (18)

Country Link
US (1) US4863922A (fr)
EP (1) EP0296879B1 (fr)
JP (1) JPH0631247B2 (fr)
AT (1) ATE86998T1 (fr)
AU (1) AU616664B2 (fr)
CA (2) CA1328262C (fr)
CY (1) CY1772A (fr)
DE (2) DE19575017I2 (fr)
DK (1) DK167684B1 (fr)
ES (1) ES2053738T4 (fr)
GR (1) GR3007407T3 (fr)
IE (1) IE62255B1 (fr)
IL (1) IL86822A (fr)
LU (1) LU88633I2 (fr)
NL (1) NL950006I2 (fr)
NZ (1) NZ225166A (fr)
PT (1) PT87832B (fr)
SG (1) SG24394G (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320487C (fr) * 1987-08-03 1993-07-20 George D. Hartman Thieno (2,3-.beta.)thiophen-2-sulfonamides utilises comme agents antig laucome
US5260453A (en) * 1988-09-23 1993-11-09 Ortho Pharmaceutical Corporation Substituted thienopyrans as antihypertensive agents
US4876271A (en) * 1988-12-20 1989-10-24 Merck & Co., Inc. Substituted thieno[3,2-b]thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors
US4929549A (en) * 1989-02-08 1990-05-29 Merck & Co., Inc. 5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors
US4946859A (en) * 1989-07-31 1990-08-07 Merck & Co., Inc. 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrothieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide
US5120757A (en) * 1989-07-31 1992-06-09 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents
CA2028496A1 (fr) * 1989-10-31 1991-05-01 Tohru Nakao Composes de thiophene et leurs applications pharmaceutiques
US5045561A (en) * 1990-04-12 1991-09-03 Merck & Co., Inc. Substituted furan sulfonamides as antiglaucoma agents
IE911192A1 (en) * 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
JP3031498B2 (ja) * 1990-04-12 2000-04-10 メルク エンド カムパニー インコーポレーテッド 抗緑内障剤としての置換芳香族スルホンアミド類
US5157129A (en) * 1990-04-18 1992-10-20 Merck & Co., Inc. Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
US5091409A (en) * 1990-05-17 1992-02-25 Merck & Co., Inc. 4-alkylamino-6-(C3-5 -hydrocarbyl)thieno[2,3-B]thiopyran-2-sulfonamide-7,7-dioxides
US5093332A (en) * 1990-10-01 1992-03-03 Merck & Co., Inc. Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents
EP0480745A3 (en) * 1990-10-12 1992-07-29 Merck & Co. Inc. Substituted dihydrothieno-thiophene-2-sulfonamides and dioxides thereof
US5216020A (en) * 1990-10-12 1993-06-01 Merck & Co., Inc. Substituted 4,5-dihydrothieno(2,3-b)thiophene-2-sulfonamides and 6,6-dioxides thereof
SG84487A1 (en) * 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
WO1992018124A1 (fr) * 1991-04-17 1992-10-29 Merck & Co., Inc. COMPOSITIONS OPHTALMIQUES RENFERMANT DES COMBINAISONS D'UN INHIBITEUR D'ANHYDRASE CARBONIQUE ET D'UN ANTAGONISTE β-ADRENERGIQUE
JPH0830067B2 (ja) * 1991-10-15 1996-03-27 メルク エンド カムパニー インコーポレーテッド 三環チエノチオピラン類
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
EP0625903B1 (fr) * 1992-02-21 1998-08-12 Alcon Laboratories, Inc. Compositions antiglaucome a usage local comprenant des inhibiteurs d'anhydrase carbonique et de beta-bloquants
EP0658211B2 (fr) * 1992-08-28 2003-12-10 Avecia Limited Procede de reduction enzymatique asymetrique permettant de produire des derives de 4 h-thieno(2,3-6)thio pyrane
JP3279671B2 (ja) * 1992-09-28 2002-04-30 鐘淵化学工業株式会社 チエノチオピラン誘導体の製造方法
TW265343B (fr) * 1993-03-22 1995-12-11 Merck & Co Inc
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
EP1251862B1 (fr) 2000-01-18 2008-10-01 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
ES2177415B1 (es) * 2000-09-04 2004-10-16 Ragactives, S.L. Procedimiento para la obtencion de 4-alquilamino-5, 6-dihidro-4h-tieno-(2,3b)-tiopiran-2-sulfonamida-7-dioxidos, e intermedios.
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2003216547A1 (en) * 2002-03-15 2003-09-29 Merck And Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2003105847A1 (fr) * 2002-06-14 2003-12-24 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
US20050239787A1 (en) * 2002-06-17 2005-10-27 Goetz Michael A Novel maxi-k channel blockers, methods of use and process for making the same
EP1515974A4 (fr) * 2002-06-17 2007-02-28 Merck & Co Inc Nouveaux bloqueurs de canaux maxi k, methodes d'utilisation et procedes de fabrication associes
WO2004019938A1 (fr) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
JP2006505572A (ja) * 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
CN1791402A (zh) * 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
EP1828198B1 (fr) 2004-12-20 2011-02-09 SK Holdings Co., Ltd. Procede servant a separer des composes thiophenes optiquement purs en utilisant la chromatographie a lit mobile simule
US7109353B2 (en) * 2004-12-28 2006-09-19 Council Of Scientific And Industrial Research Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
EP1841774A1 (fr) * 2004-12-28 2007-10-10 Usv Limited PROCÉDÉ DE SYNTHÈSE DU 5,6-DIHYDRO-4-(S)-(ÉTHYLAMINO)-6-(S)MÉTHYL-4H-THIÉNO[2,3b]THIOPYRAN-2-SULFONAMIDE-7,7-DIOXYDE HCI
ES2331162T3 (es) * 2006-04-21 2009-12-22 Zach System S.P.A. Proceso para la preparacion de dorzolamida.
EP1918293A1 (fr) * 2006-10-02 2008-05-07 Sandoz AG Procédé pour la préparation d'acide 4-oxo-thieno[2,3b]thiopyran-2-yl-sulfonique
CN101622243B (zh) 2007-02-28 2013-12-04 旭化成制药株式会社 磺酰胺衍生物
AU2008247144B2 (en) * 2007-05-07 2013-02-28 Cipla Limited Process for preparing dorzolamide
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2010061398A1 (fr) * 2008-11-27 2010-06-03 Suven Life Sciences Limited Procédé pour la préparation de chlorhydrate de dorzolamide et ses intermédiaires
EP2683724B1 (fr) 2011-03-10 2015-05-06 ZaCh System S.p.A. Procédé de réduction asymétrique
ITMI20121165A1 (it) 2012-07-03 2014-01-04 Zach System Spa Processo di riduzione asimmetrica
CN103497202B (zh) * 2013-10-23 2015-12-02 武汉武药科技有限公司 盐酸多佐胺中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416890A (en) * 1981-07-13 1983-11-22 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4426388A (en) * 1982-04-02 1984-01-17 Merck & Co., Inc. 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4499103A (en) * 1983-03-17 1985-02-12 Merck & Co., Inc. Benzothiazole-2-sulfonamide derivatives for the topical treatment of elevated intraocular pressure
DE3568431D1 (en) * 1984-12-12 1989-04-06 Merck & Co Inc Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US4677115A (en) * 1984-12-12 1987-06-30 Merck & Co., Inc. Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof
US4731368A (en) * 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation

Also Published As

Publication number Publication date
IE62255B1 (en) 1995-01-11
JPH0631247B2 (ja) 1994-04-27
CA1329211C (fr) 1994-05-03
IL86822A0 (en) 1988-11-30
IL86822A (en) 1992-01-15
DE3879292T2 (de) 1993-09-09
GR3007407T3 (fr) 1993-07-30
NL950006I2 (nl) 1997-02-03
US4863922A (en) 1989-09-05
IE881933L (en) 1988-12-26
AU616664B2 (en) 1991-11-07
NL950006I1 (nl) 1995-06-16
PT87832A (pt) 1989-05-31
SG24394G (en) 1994-06-10
ATE86998T1 (de) 1993-04-15
EP0296879B1 (fr) 1993-03-17
CA1328262C (fr) 1994-04-05
ES2053738T3 (es) 1994-08-01
AU1838788A (en) 1989-01-05
NZ225166A (en) 1991-05-28
DK348588D0 (da) 1988-06-24
DE19575017I2 (de) 2008-11-20
CY1772A (en) 1995-10-20
DK167684B1 (da) 1993-12-06
JPH01100174A (ja) 1989-04-18
PT87832B (pt) 1992-10-30
DK348588A (da) 1989-02-24
EP0296879A1 (fr) 1988-12-28
DE3879292D1 (de) 1993-04-22
ES2053738T4 (es) 2011-12-29

Similar Documents

Publication Publication Date Title
LU88633I2 (fr) Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R)
NL300098I1 (nl) Thiophene sulfonamides useful as carbonic anhydrase inhibitors.
DE3852110D1 (de) Gerät zum Insufflieren von Gas in eine Körperhöhle.
IE853143L (en) Aromatic sulfonamides, antiglaucoma agents
DK154287A (da) Substituerede oxadiazol-derivater, fremgangsmaade til fremstilling deraf og mellemprodukter til brug ved fremgangsmaaden samt laegemiddel indeholdende oxadiazolerne
LU91173I2 (fr) Ximelagatran, et les sels pharmaceutiquement acceptables de celui-ci (exanta).
NO893400L (no) Hiv protease inhibitorer egnet for behandling av aids.
DK0509752T3 (da) Oftalmiske præparater, der omfatter kombinationer af en carbonathydrolyaseinhibitor og en beta-adrenerg antagonist
DK429788A (da) Thieno(2,3-beta)thiophen-2-sulfonamid og farmaceutisk praeparat indeholdende en saadan forbindelse
ATE50257T1 (de) Kristalline form von benzothiazindioxydsalz.
DE69317343D1 (de) Verwendung eines direkten Inhibitors von Thrombin zur Herstellung eines Arzneimittels mit thrombolytischer Aktivität
IT8820050A0 (it) Metodo e apparecchiatura relativa per la produzione di una capsula trasparente.
DK435089D0 (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
IT1072824B (it) Procedimento per il trattamento di arti di una formazione sotterranea permeabnile circondanti un pozzo metanifero o simile
ES2085607T3 (es) Taco expansible de material sintetico.
ITRM910200A1 (it) Procedimento per la produzione di lenti oftalmiche a contatto.
IT8866711A0 (it) Contenitore per lenti a contatto m/r morbide e rigide
NO894189D0 (no) 4-amino-3-acylkinolonderivater og deres anvendelse som inhibitorer av mavesyresekresjon.